Compare BridgeBio Pharma Inc (BBIO) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Materials Select Sector SPDR Fund — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Materials Select Sector SPDR Fund trades at $53.25. The key difference: Materials Select Sector SPDR Fund is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | XLB | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | — |
52-Week High | $90.17 | $53.62 |
52-Week Low | $47.29 | $42.23 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
XLB trades at $52.86, up 1.32% today, with a bullish technical signal from moving averages and neutral oscillators. The materials sector benefits from AI infrastructure demand and strong Q2 earnings momentum, as noted by Zacks Investment Research on August 6, 2026. A dividend of $0.19 is scheduled for June 2026, while recent news highlights sector resilience amid geopolitical shifts.
Outlook is positive due to cyclical recovery and AI-driven demand, but risks include pricing pressures and economic sensitivity. Analysts see limited near-term upside after recent gains, with a hold rating common. Institutional interest remains strong, supporting stability amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
